New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to ...

AI in Cancer Drug Discovery could prove paradigm shifting, but what challenges does it present? And how can they be avoided?

Transparent expectation-setting and addressing potential disappointments can foster safety, reduce anxiety, and promote ...

Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

The rapid emergence and re-emergence of viral pathogens—exemplified by outbreaks of influenza, Ebola, Zika, and, most recently, SARS-CoV-2—underscore the ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

Researchers at NYU Tandon School of Engineering have developed a new method for creating microscopic drug delivery capsules ...

Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and ...

While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...